Analyst Color

For investors weary of chasing incremental upside in already high-flying chip giants like NVIDIA Corp. (NASDAQ:NVDA), Broadcom Inc. (NASDAQ:AVGO) and Advanced Micro Devices Inc. (NASDAQ:AMD), a quieter corner of the semiconductor market may offer a more attractive setup in 2026. • Credo...

Global investors are feeling pretty good about stocks, maybe a little too good. Bank of America's latest Fund Manager Survey shows the most bullish positioning since 2021 – with surging optimism, low cash levels, and hedging like it is Donald Trump's first term. The survey, conducted between...

Janux Therapeutics, Inc. (NASDAQ:JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE:BMY). San Diego-based Janux will receive up to $50 million in upfront and near-term milestone payments, with potential total payments reaching...

GE Aerospace (NYSE:GE) shares have given up their prior gain and are trading lower on Thursday. The company reported better-than-expected fourth-quarter financial results and issued a better-than-expected FY26 EPS outlook. For 2026, GE Aerospace guided to adjusted EPS of $7.10 to $7.40 versus...

The U.S. economy is entering 2026 with rare momentum: growth is accelerating, inflation remains contained and labor market stress is easing. • SPDR S&P 500 stock is trading near recent highs. What’s next for SPY stock? That rare sweet spot, often described as a "Goldilocks" setup...

Recent checks suggest that Datadog Inc (NASDAQ:DDOG) could report its fourth-quarter results significantly higher than expected, "driven by accelerating core growth, continued strong gains within the non-OAI (OpenAI) GenAI cohort and Q/Q OAI stability," according to Stifel. The Datadog Analyst:...

General Electric Co (NYSE:GE) delivered strong fourth-quarter results, with revenues, margins, and earnings ahead of expectations, while announcing a broadly in-line 2026 guidance, according to Goldman Sachs. The General Electric Analyst: Analyst Noah Poponak reiterated a Buy rating and a $338...

Johnson & Johnson's (NYSE:JNJ) shares came under pressure, despite the fourth-quarter revenue beat and in-line 2026 guidance, mainly due to stock outperformance ahead of the print and developments around the talc litigation, according to Goldman Sachs. The Analyst: Analyst Asad Haider...

Crocs Inc (NASDAQ:CROX) continues to reduce promotions and tighten wholesale receipts in North America, which could weigh on its near-term results, despite the benefit to gross margins, according to KeyBanc Capital Markets. The Crocs Analyst: Analyst Ashley Owens downgraded the rating from...

Strong productivity growth, steady regional bank fundamentals and accelerating artificial intelligence adoption may be laying the groundwork for a more durable small-cap rally than investors have seen in years. The small-cap benchmark – tracked by the iShares Russell 2000 ETF (NYSE:IWM) – has...

Commodities asset manager Sprott (NYSE:SII), known for treating precious metals as a macro signal, is evaluating the market’s structural change following one of the strongest years on record for gold and silver. The commodity sector, in its view, is no longer a trade—it's becoming a core...

BofA Securities analyst Vivek Arya said the U.S. semiconductor sector is moving into a more balanced phase, with supply and demand largely aligned and earnings expectations reset, setting up modest upside rather than a sharp rebound in 2026. • ADU stock is holding steady today. Where is ADU...

Telix Pharmaceuticals Limited (NASDAQ:TLX), a therapeutic and diagnostic radiopharmaceuticals company, on Tuesday reported its full-year revenue. • Telix Pharmaceuticals stock is testing lower boundaries. Why is TLX stock at lows? Telix Hits FY 2025 Revenue Target Australia-based Telix...

Netflix Inc (NASDAQ:NFLX) shares are trading lower on Wednesday after the company reported fourth-quarter financial results on Tuesday. While the company beat analyst estimates for revenue and earnings per share, price targets are being lowered due to guidance and the near-term outlook. •...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is gaining traction in a rare kidney disease market, with early uptake of its newly approved treatment signaling a meaningful growth inflection that could reshape the company’s revenue outlook over the next several years. Bank of America Securities (...